Abstract
Background
Methionine inhibits proliferation of breast and prostate cancer cells. Here, we determined the influence of L-methionine on functional molecular signatures in these cell lines.
Methods
MCF-7 and LNCaP cells were treated with L-methionine (5 mg/ml) for 72 h. Changes in molecular signatures of these cells were examined by microarray analysis of 15,814 probes in triplicate experiments.
Results
In LNCaP cells, 325 genes were up-regulated by methionine, and 517 genes down-regulated. In MCF-7 cells, 86 genes were up-regulated and 135 genes down-regulated. Ninety-eight genes were regulated in the same direction by methionine in both cells lines, and five other genes were changed in expression in opposite directions.
Conclusion
Several of the up-regulated genes encode proteins involved in cellular redox regulation, suggesting that methionine may enhance antioxidant mechanisms. Many of the down-regulated genes belong to protein kinase families that may be related to the anti-proliferative effects of methionine on breast and prostate cancer cells.
Similar content being viewed by others
References
Anderson ME (1998) Glutathione: an overview of biosynthesis and modulation. Chem Biol Interact 111–112:1–14
Bello RI, Gomez-Diaz C, Navarro F, Alcain FJ, Villalba JM (2001) Expression of NAD(P)H:quinone oxidoreductase 1 in HeLa cells: role of hydrogen peroxide and growth phase. J Biol Chem 276:44379–44384
Benavides MA, Oelschlager DK, Zhang HG, Stockard CR, Vital-Reyes VS, Katkoori VR, Manne U, Wang W, Bland KI, Grizzle WE (2007) Methionine inhibits cellular growth dependent on the p53 status of cells. Am J Surg 193:274–283
Benavides MA, Hagen KL, Fang W, Du P, Lin S, Moyer MP, Yang W, Bland KI, Grizzle WE, Bosland MC (2010) Suppression by L-methionine of cell cycle progression in LNCaP and MCF-7 cells but not benign cells. Anticancer Res (Accepted for publication)
Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Statist Soc Ser B 57:289–300
Dalle-Donne I, Rossi R, Colombo G, Giustarini D, Milzani A (2009) Protein S-glutathionylation: a regulatory device from bacteria to humans. Trends Biochem Sci 34:85–96
Du P, Kibbe WA, Lin SM (2007) nuID: a universal naming scheme of oligonucleotides for illumina, affymetrix, and other microarrays. Biol Direct 2:16
Fagerholm R, Hofstetter B, Tommiska J, Aaltonen K, Vrtel R, Syrjakoski K, Kallioniemi A, Kilpivaara O, Mannermaa A, Kosma VM, Uusitupa M, Eskelinen M, Kataja V, Aittomaki K, von Smitten K, Heikkila P, Lukas J, Holli K, Bartkova J, Blomqvist C, Bartek J, Nevanlinna H (2008) NAD(P)H: quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer. Nat Genet 40:844–853
Forthoffer N, Gomez-Diaz C, Bello RI, Buron MI, Martin SF, Rodriguez-Aguilera JC, Navas P, Villalba JM (2002) A novel plasma membrane quinone reductase and NAD(P)H: quinone oxidoreductase 1 are upregulated by serum withdrawal in human promyelocytic HL-60 cells. J Bioenerg Biomembr 34:209–219
Gallagher S (2001) Quantitation of nucleic acids with absorption spectroscopy. Curr Protoc Protein Sci (Appendix 4: Appendix 4K)
Giustarini D, Rossi R, Milzani A, Colombo R, Dalle-Donne I (2004) S-glutathionylation: from redox regulation of protein functions to human diseases. J Cell Mol Med 8:201–212
Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA, Murphy GP (1983) LNCaP model of human prostatic carcinoma. Cancer Res 43:1809–1818
Huang E, Ishida S, Pittman J, Dressman H, Bild A, Kloos M, D’Amico M, Pestell RG, West M, Nevins JR (2003) Gene expression phenotypic models that predict the activity of oncogenic pathways. Nat Genet 34:226–230
Ji Q, Chang L, VanDenBerg D, Stanczyk FZ, Stolz A (2003) Selective reduction of AKR1C2 in prostate cancer and its role in DHT metabolism. Prostate 54:275–289
Ji Q, Aoyama C, Nien YD, Liu PI, Chen PK, Chang L, Stanczyk FZ, Stolz A (2004) Selective loss of AKR1C1 and AKR1C2 in breast cancer and their potential effect on progesterone signaling. Cancer Res 64:7610–7617
Judde JG, Ellis M, Frost P (1989) Biochemical analysis of the role of transmethylation in the methionine dependence of tumor cells. Cancer Res 49:4859–4865
Lin SM, Du P, Huber W, Kibbe WA (2008) Model-based variance-stabilizing transformation for Illumina microarray data. Nucleic Acids Res 36:e11
Lou H, Du S, Ji Q, Stolz A (2006) Induction of AKR1C2 by phase II inducers: identification of a distal consensus antioxidant response element regulated by NRF2. Mol Pharmacol 69:1662–1672
Mazzocco M, Maffei M, Egeo A, Vergano A, Arrigo P, Di Lisi R, Ghiotto F, Scartezzini P (2002) The identification of a novel human homologue of the SH3 binding glutamic acid-rich (SH3BGR) gene establishes a new family of highly conserved small proteins related to thioredoxin superfamily. Gene 291:233–239
Metayer S, Seiliez I, Collin A, Duchene S, Mercier Y, Geraert PA, Tesseraud S (2008) Mechanisms through which sulfur amino acids control protein metabolism and oxidative status. J Nutr Biochem 19:207–215
Pratt SE, Pollak MN (1993) Estrogen and antiestrogen modulation of MCF7 human breast cancer cell proliferation is associated with specific alterations in accumulation of insulin-like growth factor-binding proteins in conditioned media. Cancer Res 53:5193–5198
SantaCruz KS, Yazlovitskaya E, Collins J, Johnson J, DeCarli C (2004) Regional NAD(P)H: quinone oxidoreductase activity in Alzheimer’s disease. Neurobiol Aging 25:63–69
Shrivastava A, Nunn AD, Tweedle MF (2009) Designer peptides: learning from nature. Curr Pharm Des 15:675–681
Smyth G (2004) Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol (3: Article 3)
Sweet-Cordero A, Mukherjee S, Subramanian A, You H, Roix JJ, Ladd-Acosta C, Mesirov J, Golub TR, Jacks T (2005) An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis. Nat Genet 37:48–55
Takahashi K, Suzuki K (1993) Association of insulin-like growth-factor-I-induced DNA synthesis with phosphorylation and nuclear exclusion of p53 in human breast cancer MCF-7 cells. Int J Cancer 55:453–458
Thomas T, Thomas TJ (2001) Polyamines in cell growth and cell death: molecular mechanisms and therapeutic applications. Cell Mol Life Sci 58:244–258
Toppo S, Vanin S, Bosello V, Tosatto SC (2008) Evolutionary and structural insights into the multifaceted glutathione peroxidase (Gpx) superfamily. Antioxid Redox Signal 10:1501–1514
Vazquez E, Ferrer-Miralles N, Mangues R, Corchero JL, Schwartz S Jr, Villaverde A (2009) Modular protein engineering in emerging cancer therapies. Curr Pharm Des 15:893–916
Yin L, Xiang Y, Zhu DY, Yan N, Huang RH, Zhang Y, Wang DC (2005) Crystal structure of human SH3BGRL protein: the first structure of the human SH3BGR family representing a novel class of thioredoxin fold proteins. Proteins 61:213–216
Acknowledgments
Supported in part by a Supplement to NIH Grant No. R01CA116195. The authors thank Dr Jin-Qiang Chen and Dr Daniel Guimaraes Tiezzi for technical and edition assistance.
Conflict of interest statement
We declare that we have no conflict of interest.
Author information
Authors and Affiliations
Corresponding authors
Electronic supplementary material
Below is the link to the electronic supplementary material.
432_2010_897_MOESM1_ESM.pdf
Supplemental Table 1: Genes with altered expression in LNCaP cells treated with L-methionine 5 mg/ml for 72 h. Significant changes in expression were observed in a total of 842 genes out of 15,814 probes examined, with 325 genes up-regulated and 517 genes down-regulated. (PDF 208 kb)
432_2010_897_MOESM2_ESM.pdf
Supplemental Table 2: Genes with altered expression in MCF-7 cells treated with L-methionine 5 mg/ml for 72 h. Significant changes in expression were observed in a total of 221 genes out of 15,814 probes examined, with 86 genes were up-regulated and 135 genes down-regulated. (PDF 80 kb)
Rights and permissions
About this article
Cite this article
Benavides, M.A., Hu, D., Baraoidan, M.K. et al. L-methionine-induced alterations in molecular signatures in MCF-7 and LNCaP cancer cells. J Cancer Res Clin Oncol 137, 441–453 (2011). https://doi.org/10.1007/s00432-010-0897-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-010-0897-5